Q-omics provides the consensus-scored ATOH8 profile across patient tissues and cancer cell-line models. ATOH8 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ATOH8 is differentially expressed in 16, with the highest sampling consensus in KICH. Additionally, ATOH8 RNA expression shows 21,690 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, KICH, and LSCC as cancer lineages where ATOH8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATOH8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATOH8 survival associations across molecular data types. ATOH8 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATOH8 RNA expression–survival associations across cancer types. High ATOH8 expression shows unfavorable associations in LUSC, but favorable associations in KIRC, PAAD, LGG, SKCM and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ATOH8 RNA expression.
This table summarizes ATOH8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ATOH8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATOH8 shows lower tumor expression in KICH, COAD, LUSC, LUAD, HNSC and STAD. The KICH box plot shows higher ATOH8 RNA expression in normal versus tumor tissue (log2 FC = −2.958, t-test p < 0.001).
This table shows molecular features associated with ATOH8 in patient tissues and cancer cell lines. In patient samples, ATOH8 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ATOH8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and SOFT_TISSUE.
